Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL DUCHENNE MUSCULAR DYSTROPHY INDUSTRY
2.1 Summary about Duchenne Muscular Dystrophy Industry
2.2 Duchenne Muscular Dystrophy Market Trends
2.2.1 Duchenne Muscular Dystrophy Production & Consumption Trends
2.2.2 Duchenne Muscular Dystrophy Demand Structure Trends
2.3 Duchenne Muscular Dystrophy Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Deflazacort
4.2.2 Prednisone
4.2.3 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Male
4.3.2 Female
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Deflazacort
5.2.2 Prednisone
5.2.3 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Male
5.3.2 Female
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Deflazacort
6.2.2 Prednisone
6.2.3 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Male
6.3.2 Female
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Deflazacort
7.2.2 Prednisone
7.2.3 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Male
7.3.2 Female
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Deflazacort
8.2.2 Prednisone
8.2.3 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Male
8.3.2 Female
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Deflazacort
9.2.2 Prednisone
9.2.3 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Male
9.3.2 Female
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 PTC Therapeutics
10.1.2 Sarepta Therapeutics
10.1.3 Bristol-Myers Squibb
10.1.4 ITALFARMACO
10.1.5 BioMarin
10.1.6 Daiichi Sankyo
10.1.7 Solid Biosciences
10.1.8 Summit Therapeutics
10.1.9 FibroGen
10.1.10 NS Pharma
10.1.11 Pfizer
10.1.12 ReveraGen BioPharma
10.1.13 Wave Life
10.1.14 Genethon
10.1.15 Santhera Pharmaceuticals
10.2 Duchenne Muscular Dystrophy Sales Date of Major Players (2017-2020e)
10.2.1 PTC Therapeutics
10.2.2 Sarepta Therapeutics
10.2.3 Bristol-Myers Squibb
10.2.4 ITALFARMACO
10.2.5 BioMarin
10.2.6 Daiichi Sankyo
10.2.7 Solid Biosciences
10.2.8 Summit Therapeutics
10.2.9 FibroGen
10.2.10 NS Pharma
10.2.11 Pfizer
10.2.12 ReveraGen BioPharma
10.2.13 Wave Life
10.2.14 Genethon
10.2.15 Santhera Pharmaceuticals
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
